Effects of surface-bound and intravenously administered heparin on cell-surface interactions: Inflammation and coagulation

Perfusion (United Kingdom)

Volumn 28, Issue 3, 2013, Pages 263-271

  Johnson, G ^a   Curry, B ^b   Cahalan, L ^a   Prater, R ^b   Biggerstaff, J ^b   Hussain, A ^a   Gartner, M ^a   Cahalan, P ^a  

^a Ension Inc   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

anti thrombin; flow cytometry; heparin; leukocyte activation; platelet activation

Indexed keywords

HEPARIN;

ANESTHETIC EQUIPMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CELL ACTIVATION; CHEMICAL BINDING; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION; MICROPERFUSION CIRCUIT; MONOCYTE; PRIORITY JOURNAL; SURFACE PROPERTY; THROMBOCYTE ACTIVATION;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; COATED MATERIALS, BIOCOMPATIBLE; EXTRACORPOREAL CIRCULATION; HEPARIN; HUMANS; INFLAMMATION; LYMPHOCYTE ACTIVATION; MONOCYTES; NEUTROPHILS; PLATELET ACTIVATION; SURFACE PROPERTIES;

EID: 84876714868     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659113475834     Document Type: Article

References (41)

1. Wendel HP, Scheule AM, Eckstein FS, et al. Hemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces. Perfusion. 1999 ; 14: 21-28 (Pubitemid 29070649)
2. Weerwind PW, van der Veen FH, Lindhout T, et al. Ex vivo testing of heparin-coated extracorporeal circuits: bovine experiments. Int J Artif Organs. 1998 ; 21: 291-298 (Pubitemid 28322636)
3. Grady RM, Eisenberg PR, Bridges ND. Rational approach to use of heparin during cardiac catheterization in children. J Am Coll Cardiol. 1995 ; 25: 325-329
4. Weber N, Wendel HP. Quality assessment of heparin coatings by their binding capacities of coagulation and complement enzymes. J Biomater Appl. 2000 ; 15: 8-22
5. Wendel HP and, Ziemer G. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation. Eur J Cardiothorac Surg. 1999 ;: 342-350 (Pubitemid 29443972)
6. Pasche B, Kodama K, Larm O, et al. Thrombin inactivation of surfaces with covalently bonded heparin. Thromb Res. 1986 ; 44: 739-748 (Pubitemid 17228876)
7. Andersson J, Sanchez J, Ekdahl KN, Elgue G, Nilsson B, Larsson R. Optimal heparin surface concentration and antithrombin binding capacity as evaluated with human non-anticoagulated blood in vitro. J Biomed Mater Res A. 2003 ; 67: 458-466 (Pubitemid 37522451)
8. Pasche B, Swedenborg J, Hedin U, et al. Thrombogenicity of the vessel wall after single and repeated injury. Thromb Res. 1991 ; 62: 531-543
9. Kodama K, Pasche B, Olsson P, et al. Antithrombin III binding to surface immobilized heparin and its relation to F Xa inhibition. Thromb Haemost. 1987 ; 58: 1064-1067
10. Blezer R, Cahalan L, Cahalan PT, et al. Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IXa generation. Blood Coagul Fibrinolysis. 1998 ; 9: 435-440 (Pubitemid 28346514)
11. Antithrombin.. :
12. West RH, Paul AJ, Hibbert S, et al. Correlation of the surface chemistries of polymer bioactive coatings, with their biological performances. J Mater Sci Mater Med. 1995 ; 6: 63-67
13. Johnson G, Curry B, Cahalan L, et al. In vitro assessment of blood compatibility: residual and dynamic markers of cellular activation. J Biomater Appl. 2011 ;:
14. Passacquale G, Vamadevan P, Pereira L, et al. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLOSone. 2011 ; Volume 6 ( Issue 10 ):
15. Sanchez J, Elgue G, Riesenfeld J, et al. Inhibition of the plasma contact activation system of immobilized heparin; relation to surface density of functional antithrombin binding sites. J Biomed Mater Res. 1997 ; 37: 37-42 (Pubitemid 27427562)
16. Barnard MR, Linden MD, Frelinger AL, et al. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb and Haemost. 2005 ; 3: 2563-2570 (Pubitemid 41727174)
17. Reddy M, Eirikis E, Davis C, et al. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods. 2004 ; 293: 127-142 (Pubitemid 39468338)
18. Seizer P, Gawaz M, May AE. Platelet-monocyte interactions - a dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem. 2008 ; 15: 1976-1980
19. Dabbagh K, Chambers RC, Laurent GJ. From clot to collagen: coagulation peptides in interstitial lung disease. Eur Respir J. 1998 ; 11: 1002-1005 (Pubitemid 28281013)
20. Levi M and, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010 ; 38: S26
21. Amara U, Rittirsch D, Flierl M, et al Current topics in complement II. Lambris J.D., ed. 2008 :
22. Gorbet MB, Sefton M. Biomaterial-associated thrombosis; roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004 ; 25: 5681-5703 (Pubitemid 38624449)
23. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003 ; 17: S1 - S5
24. Riddel JP, Aouizerat BE, Miaskowski C, et al. Theories of blood coagulation. J Pediatr Oncol Nurs. 2007 ; 24: 123-131
25. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997 ; 90: 3819-3843 (Pubitemid 27484034)
26. Frick IM, Bjorck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost. 2007 ; 98: 497-502 (Pubitemid 47412875)
27. Ovrum E, Mollnes TE, Fosse E, et al. High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann Thorac Surg. 1995 ; 60: 1755-1761 (Pubitemid 26079166)
28. John R, Sandhya P, Hrabe J, et al. Activation of endothelial and coagulation systems in left ventricular assist device recipients. Ann Thorac Surg. 2009 ; 88: 1171-1179
29. Wilhelm CR, Ristich J, Kormos RL, et al. Monocyte tissue factor expression and ongoing complement generation in ventricular assist device patients. Ann Thorac Surg. 1998 ; 65: 1071-1076
30. Ekdahl KN, Lambris JD, Elwing H, et al. Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies. Adv Drug Deliv. 2011 ; 63: 1042-1050
31. Blockmans D, Deckmyn H, Vermylen J. Platelet actuation. Blood Rev. 1995 ; 9: 143-156
32. Sims PJ, Wiedmar T. Induction of cellular procoagulant activity by the membrane attack complex of complement. Semin Cell Biol. 1995 ; 6: 275-282
33. Jy W, Mao WW, Horstman L, Tao J, Ahn YS. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cells Mol Dis. 1995 ; 21: 217-231 (Pubitemid 26083518)
34. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol. 1996 ; 28: 345-353 (Pubitemid 26274326)
35. Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Heamost. 2000 ; 83: 937-943 (Pubitemid 30411697)
36. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 1999 ; 19: 2251-2262 (Pubitemid 29422260)
37. Ye A, Takano R, Hayashi K, et al. Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction. Thromb Res. 1998 ; 89: 263-270 (Pubitemid 28318381)
38. Smith SA. The cell-based model of coagulation. Journal of Veterinary Emergency and Critical Care. 2009 ; 19 (1). 3-10
39. Garred P, Mollnes TE. Immobilized heparin inhibits the increase in leukocyte surface expression of adhesion molecules. Artif Organs. 1997 ; 21: 293-299 (Pubitemid 27148631)
40. Lappegård KT, Fung M, Bergseth G, et al. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg. 2004 ; 77: 932-941 (Pubitemid 38271064)
41. Sokolov A, Hellerud BC, Tennessen TI, et al. Activation of coagulation and platelets by candidate membranes of implantable devices in a whole blood model without soluble anticoagulant. J Biomed Mater Res Part A. 2013 ; 101A: 575-581